Radiation therapy with concurrent paclitaxel chemotherapy following surgery is an effective treatment for high-risk endometrial cancer, according to a study reported by Cho et al in the International Journal of Radiation Oncology • Biology • Physics Endometrial...
The ASCO Clinical Practice Guidelines Committee and the Cancer Care Ontario (CCO) program in evidence-based care have released a clinical practice guideline on systemic therapy in men with metastatic castration-resistant prostate cancer. The guideline is reported by Basch et al in the Journal of...
The investigational agent VT-122 appeared to benefit survival when combined with sorafenib (Nexavar) in patients with advanced hepatocellular carcinoma, according to data presented at the 8th Annual International Liver Cancer Association Conference in Kyoto, Japan. Researchers reported an 11-month...
In a retrospective study reported in JAMA Surgery, Black et al found that the sentinel lymph node biopsy rate was lower and risk for lymphedema higher in black vs white women with early-stage breast cancer in the Medicare population. Study Details The study used the Surveillance, Epidemiology,...
A phase Ib clinical trial of the tablet form of olaparib, a PARP inhibitor, in combination with paclitaxel and carboplatin chemotherapy in heavily pretreated patients with advanced-stage ovarian cancer finds the drug to be safe and effective, especially in those women with BRCA gene mutations. The...
Maintenance rituximab (Rituxan) has been shown to improve progression-free survival vs observation in low-tumor-burden follicular lymphoma. In the Eastern Cooperative Oncology Group (ECOG) E4402 Trial (RESORT), reported in the Journal of Clinical Oncology, Kahl et al found no significant difference ...
When factoring in what is now known about breast cancer biology and heterogeneity, breast-conserving therapy may offer a greater survival benefit over mastectomy to women with early-stage, hormone receptor–positive disease, according to research from The University of Texas MD Anderson Cancer ...
An experimental regimen of once-weekly breast irradiation following lumpectomy provides more convenience to patients at a lower cost, results in better completion rates of prescribed radiation treatment, and produces cosmetic outcomes comparable to the current standard of daily radiation. These...
Despite its acceptance as standard of care for early-stage breast cancer almost 25 years ago, barriers still exist that preclude patients from receiving breast-conserving therapy, with some still opting for a mastectomy, according to research from The University of Texas MD Anderson Cancer Center....
A new breast cancer vaccine candidate, GP2, provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug. These findings were presented at the 2014 Breast...
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to the anti–PD-1 antibody pembrolizumab (Keytruda) for the treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs. Pembrolizumab is intended for use following...
The American Society of Clinical Oncology has released a new clinical practice guideline on chemotherapy and targeted therapy for women with advanced HER2-negative or unknown HER2 status breast cancer. The guideline is published in the Journal of Clinical Oncology. In formulating the consensus...
A survey of 150 women newly diagnosed with breast cancer provides new insight into factors that influence women’s decisions to undergo contralateral prophylactic mastectomy. This is one of the first studies to look at women’s breast surgery preferences prospectively, before they undergo ...
A new analysis of 30-day post-surgery complications among more than 18,000 women with breast cancer undergoing bilateral and unilateral mastectomy with breast reconstruction found that complications were generally rare for either type of surgery, with an overall rate of complications of 5.3%....
A large study conducted through the BC Cancer Agency in British Columbia, Canada, reports that adding family physician–signed reminder letters to the standard schedule of postcard reminders substantially improves return rates for screening among women who are overdue for such screening. In a...
An analysis of data from 12 large clinical trials found that the cancer’s pathologic response to neoadjuvant chemotherapy and tumor subtype are strong predictors of locoregional breast cancer recurrence. According to the researchers, the study showed that these two predictors may be more...
A retrospective review of records at an academic cancer center in Ontario, Canada, found that referrals for genetic counseling and the rates of genetic testing performed almost doubled over the 6-month period after Angelina Jolie announced she underwent a preventive double mastectomy because she...
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy extended survival over systemic therapy alone in well-selected candidates with peritoneal hepatocellular carcinoma, according to the results of a small retrospective trial reported by Tabrizian et al in the Journal of...
In the phase III CENTRIC EORTC 26071-22072 trial reported in The Lancet Oncology, Stupp et al found that adding the selective αvβ3 and αvβ5 integrin inhibitor cilengitide to standard temozolomide chemoradiotherapy produced no survival benefit in newly diagnosed glioblastoma...
Circulating tumor cell clusters—clumps of from 2 to 50 tumor cells that break off a primary tumor and are carried through the bloodstream—appear to be much more likely to cause metastasis than are single circulating tumor cells, according to a study from investigators at the...
A subset of patients with stage III colon cancer had improved survival rates when treated with irinotecan-based therapy, according to a new study in Gastroenterology. When added to the standard chemotherapy treatment—fluorouracil [5-FU] and leucovorin—adjuvant irinotecan therapy...
Although studies have shown that women with a false-positive result from mammography screening have an increased risk of developing breast cancer later in life compared with women who only have negative results, a new Danish study examined how much of the excess risk was due to misclassification...
Sequencing RNA, not just DNA, could help doctors predict how prostate cancer tumors will respond to treatment, according to research published in the journal Genome Biology. Because a tumor’s RNA shows the real-time changes a treatment is causing, the authors believe that this could be a...
Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have identified and characterized mutated forms of the gene that encodes BCR-ABL, the unregulated enzyme driving chronic myeloid leukemia (CML). The findings by Zabriskie et al were published in Cancer Cell. Although tyrosine ...
A new study reveals that the United States has experienced widespread adoption of robot-assisted prostatectomy to treat prostate cancer in recent years. The findings, reported by Chang et al in BJU International, also showed that although such surgeries are more expensive than traditional...
Epidermal growth factor receptor (EGFR) mutations found in the circulating-free tumor DNA from the plasma of advanced non–small cell lung cancer (NSCLC) patients correlates well with the EGFR mutations from patient-matched tumor tissue DNA, according to new data reported by Douillard et...
In a phase III Australian/New Zealand trial (TROG 03.04 RADAR) reported in The Lancet Oncology, Denham et al found no differences in prostate cancer–specific or all-cause mortality with intermediate-term androgen suppression and radiotherapy or short-term suppression plus radiotherapy with or ...
In a retrospective study reported in the Journal of Clinical Oncology, Kollmannsberger et al found that active surveillance for patients with clinical stage I testicular cancer is associated with very good outcomes. Most relapses occurred within 2 years of orchiectomy in patients with nonseminoma...
Previous research has suggested that women with Hodgkin lymphoma who receive certain types of chemotherapy or radiotherapy are at increased risk of future infertility, but there was insufficient information to provide patients with detailed advice. In a study published in the Journal of the...
Approximately half of all patients with posterior uveal melanoma develop metastatic liver disease within 15 years. Although brachytherapy utilizing current isotopes may be hindered by associated toxicities, the isotope ruthenium-106 has been reintroduced into the U.S. market. In a study published...
In a study reported in JAMA Dermatology, Youlden et al found that the incidence of Merkel cell carcinoma in Queensland, Australia, a known high-risk area, increased by 2.6% annually between 1993 and 2010. Five-year relative survival was 41%, with significantly better survival found in patients aged ...
An international scientific collaboration led by Baylor College of Medicine as part of The Cancer Genome Atlas initiative has revealed clues about genetic alterations that may contribute to a rare form of kidney cancer. The study, which describes the landscape of somatic genomic alterations of...
Transrectal ultrasound guided biopsy is the standard for detecting prostate cancer, but international reports have suggested that the risks associated with the procedure are increasing. In a new nationwide population-based study reported in The Journal of Urology, Swedish researchers found that 6%...
Although the majority of patients with mantle cell lymphoma respond to initial therapy, the duration of remission is typically short (1.5 to 3 years). Although bortezomib (Velcade) and lenalidomide (Revlimid) as single agents have been associated with response rates as high as 53% in patients with...
The 1964 Surgeon General’s Report on Smoking and Health started a culture change in the way Americans viewed tobacco and their health, and has saved countless million of lives. But the 1964 Report remained scientifically ambiguous on certain vital issues, such as the effect smoking had on the ...
Despite advances in the treatment of diffuse large B-cell lymphoma (the most common subtype of non-Hodgkin lymphoma), including the introduction of rituximab (Rituxan), diffuse large B-cell lymphoma patients living in low-socioeconomic-status neighborhoods have a 34% greater risk of dying from...
Updated recommendations (the Lugano Classification) for initial evaluation, staging, and assessment of response in patients with Hodgkin lymphoma and non-Hodgkin lymphoma (NHL) have been presented in the Journal of Clinical Oncology by Cheson et al. The recommendations are the result of two...
Barrington et al in the International Conference on Malignant Lymphomas Imaging Working Group have presented updated consensus guidelines on 18F-fluorodeoxyglucose (FDG) positron-emission tomography (PET)-computed tomography (CT) for staging and response assessment for FDG-avid lymphomas. The...
Despite updates on cancer screening guidelines from several medical societies—including ASCO, the American Cancer Society, the American Urological Association, the American College of Physicians, as well as the U.S. Preventive Services Task Force—which use life expectancy and/or age as...
In a UK population-based cohort study of associations between body mass index (BMI) and 22 specific cancers reported in The Lancet by Bhaskaran et al, positive associations were found for most cancers and were strongest for uterine, gallbladder, kidney, cervix, thyroid, liver, colon, ovarian, and...
Use of panitumumab (Vectibix) and cetuximab (Erbitux) in patients with metastatic colorectal cancer decreased significantly after the publication of clinical trial evidence that anti-EGFR antibodies should be restricted to wild-type KRAS tumors, subsequent ASCO guidelines recommending testing for...
BluePrint in combination with MammaPrint molecular subtyping reclassified more than 20% of breast cancer patients into a different subgroup compared with conventional assessment, according to the results of the prospective Neoadjuvant Breast Registry Symphony Trial (NBRST). In Annals of Surgical...
Researchers at Roswell Park Cancer Institute (RPCI) have found that the expression pattern of a unique class of tumor-associated antigens, known as the MAGE cancer-testis antigens (CTAs), correlates with clinical outcome in epithelial ovarian cancer. Based on their findings, the researchers have...
The 13-year follow-up of the European Randomized Study of Screening for Prostate Cancer (ERSPC), reported by Schröder et al in The Lancet, showed that prostate-specific antigen (PSA) screening in men aged 55 to 69 years is associated with a 21% reduction in risk of prostate cancer mortality...
In a single-center retrospective matched case-control study reported in JAMA Surgery, Franken et al found no significant differences in 30-day morbidity or mortality, positive margin status, major complications, hospital stay, or readmission rates for laparoscopic vs open partial hepatic resection...
In a study reported in a letter to The New England Journal of Medicine, Dreijerink et al in the International Breast Cancer in MEN1 Study Group identified a high risk of breast cancer in women with multiple endocrine neoplasia type 1 (MEN1). MEN1 is caused by germline mutations in the MEN1...
Researchers at the Children’s Medical Center Research Institute at UT Southwestern (CRI) have identified a gene that contributes to the development of several childhood cancers, in a study conducted in mouse models. If the findings prove to be applicable to humans, the research could...
Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all steps of the clinical trial are most likely to undergo a biopsy, according to a study by Gritz et al published in Cancer Epidemiology, Biomarkers & Prevention. The Prostate Cancer Prevention Trial, ...
The BRAF inhibitor vemurafenib (Zelboraf) is approved for treatment of BRAF-mutated metastatic melanoma. There are reports indicating that vemurafenib may be active in the treatment of intracranial neoplasms with BRAF mutations. As reported in the Journal of Clinical Oncology, Lee et al from...
A new analysis confirms that U.S. lung cancer rates are declining overall, but it also uncovers previously unrecognized trends related to cancer subtype, sex, race/ethnicity, and age. Published early online in Cancer, the findings provide a more accurate picture of the state of lung cancer in the...